C Galván-Casas1, A Catalá2, G Carretero Hernández3, I Garcia-Doval4. 1. Hospital Universitario de Móstoles, Madrid, Spain. 2. Hospital Plató, Barcelona, Spain. 3. Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas, Spain. 4. Research Unit, Fundación Piel Sana Academia Española de Dermatología y Venereología, Madrid, Spain.
Dear Editor, Dr Drago et al. are right to point out that our paper did not provide data on enanthems.1, 2 As the data collection form did not include the description of mucous membranes, they might have not been explored in many patients. We have reported and included in the supplementary material a few cases that were noticed by their doctors and were the first descriptions of enanthem in COVID‐19. Given the low number of cases and their non‐systematic acquisition, we avoided any analysis of these data.We disagree with the suggestion of collecting data for a study and later asking for consent. All the included patients gave informed consent before incorporating their data in the study. We feel that the limitations of this strategy are already highlighted in the discussion of the paper and do not seriously bias the results of the study.Regarding serologic testing, we agree that it could have been useful, but it was not available at the time that the study was done, and diagnosis was made using Polymerase Chain Reaction.We also agree on the discussed hypotheses about coinfection or reactivation and the need for further studies to test them.
Authors: C Galván Casas; A Català; G Carretero Hernández; P Rodríguez-Jiménez; D Fernández-Nieto; A Rodríguez-Villa Lario; I Navarro Fernández; R Ruiz-Villaverde; D Falkenhain-López; M Llamas Velasco; J García-Gavín; O Baniandrés; C González-Cruz; V Morillas-Lahuerta; X Cubiró; I Figueras Nart; G Selda-Enriquez; J Romaní; X Fustà-Novell; A Melian-Olivera; M Roncero Riesco; P Burgos-Blasco; J Sola Ortigosa; M Feito Rodriguez; I García-Doval Journal: Br J Dermatol Date: 2020-06-10 Impact factor: 11.113